Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Buy" by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has been assigned an average recommendation of "Buy" from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $222.71.

KRYS has been the topic of a number of analyst reports. Citigroup increased their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright lifted their price objective on shares of Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. Finally, Chardan Capital increased their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently modified their holdings of the business. FMR LLC grew its position in Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after purchasing an additional 21,133 shares during the last quarter. Vanguard Group Inc. increased its stake in Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after buying an additional 28,707 shares during the period. Avoro Capital Advisors LLC raised its position in Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after buying an additional 6,600 shares during the last quarter. Hood River Capital Management LLC lifted its stake in shares of Krystal Biotech by 2.1% in the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after acquiring an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after acquiring an additional 71,200 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $162.29 on Tuesday. The firm has a market cap of $4.69 billion, a price-to-earnings ratio of 54.28 and a beta of 0.79. The firm has a 50 day simple moving average of $174.63 and a 200-day simple moving average of $171.10. Krystal Biotech has a one year low of $141.72 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 earnings per share. Equities analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.